229. Dr. Marty Makary: Vaccines, Chronic Disease, Drug Prices & Hormone Therapy - The Ultimate Human with Gary Brecka Recap

Podcast: The Ultimate Human with Gary Brecka

Published: 2026-01-09

Duration: 1 hr 20 min

Guests: Dr. Marty Makary

Summary

Dr. Marty Makary, FDA Commissioner, discusses significant reforms in the U.S. healthcare system focused on transparency, drug pricing, and medical education. The episode explores the FDA's efforts to improve public health through dietary guideline changes, hormonal therapy corrections, and vaccine transparency.

What Happened

Dr. Marty Makary highlights the U.S. healthcare system's shortcomings, noting that despite high spending, the nation suffers from significant chronic disease prevalence, with 42% of children affected. The FDA, which oversees a substantial portion of the U.S. economy, is implementing reforms to enhance food safety and drug approvals, aiming to deliver more effective treatments and healthier food for children.

Makary discusses the FDA's decision to remove petroleum-based food dyes from the U.S. food supply and their efforts to rewrite the Dietary Guidelines and Food Pyramid alongside the USDA. These changes emphasize natural saturated fats, protein, and fiber, aiming to improve public health and reduce chronic disease rates.

The episode delves into the misconceptions surrounding hormone replacement therapy (HRT). The Women's Health Initiative study in 2002 incorrectly linked HRT to increased breast cancer risk. Starting HRT within 10 years of menopause can significantly reduce symptoms and health risks, with the FDA now removing black box warnings on these therapies.

Makary addresses vaccine transparency, noting that the current schedule recommends 72 to 79 vaccines for children. The FDA is committed to making adverse events and vaccine data more transparent to the public, encouraging informed decision-making.

The discussion extends to the microbiome's role in health, where antibiotics administered early in life can increase risks for diseases like celiac and Crohn's. The FDA is exploring ways to mitigate these risks by promoting gold standard science for drug approvals and considering new therapies like peptides and stem cells.

Efforts to lower drug prices include making more drugs available over-the-counter to increase competition. The FDA is also reducing the time and cost associated with developing biosimilars, thus fostering a more competitive market and lowering prices for consumers.

Key Insights

• The U.S. healthcare system spends significantly yet 42% of children are affected by chronic diseases, highlighting inefficiencies in addressing public health.
• The FDA is removing petroleum-based food dyes from the U.S. food supply and revising the Dietary Guidelines to emphasize natural saturated fats, protein, and fiber.
• Starting hormone replacement therapy within 10 years of menopause can reduce symptoms and health risks, and the FDA has removed black box warnings from these therapies.
• The FDA aims to increase vaccine transparency by making adverse event data accessible, while the current schedule recommends 72 to 79 vaccines for children.